Podcasts about Brem

Salut, Hola und Ciao (hier bitte die Eurovision-Hymne einspielen), wir begrüßen unsere Fans aus Bremão und aller Welt in 2025! Wichtiges Statement vorab: Wir würden uns freuen, wenn wir dieses Jahr alle mal die Wachteln in Ruhe lassen könnten. Danke! Was wir uns sonst für Neujahrsvorsätze gemacht haben, hört ihr in dieser Folge. Außerdem erzählen wir, wie unsere erste Datenight seit Geburt in die Rotze gefallen ist und welche wilden Partypläne Ariana für ihren Geburtstag schmiedet. Also: Wer wissen will, warum Spazieren keine Bewegung ist, warum wir auf 1,5x durch 2025 gleiten und wo eigentlich Bremão liegt, sollte MAD CLUB hören jetzt zu einer Priorität machen. Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte: https://linktr.ee/madclubpodcast Du möchtest Werbung in diesem Podcast schalten? Dann erfahre hier mehr über die Werbemöglichkeiten bei Seven.One Audio: https://www.seven.one/portfolio/sevenone-audio

Fabien de Brem, country manager de Klipsch en France, est l'invité du Talk décideurs du Figaro.Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Brem Phipps joins the JMO Podcast for this one. After being baptized into walleye fishing on Ft. Peck in eastern Montana, Brem has more recently shown consistent success in some of the most competitive tournaments on the big reservoir. Winning the Crooked Creek Tournament with a two day total of 96.3 lbs for ten fish. In this interview we get to know a young 24 year old angler that has an unstoppable drive to be the best tournament walleye angler he can be. Forward facing sonar is the central piece of tech that Brem uses to find and catch giant Ft. Peck walleyes. Listen here on how this young man is getting it done. Montana Fish Wildlife and Parks - FWP.MT.GOV/AIS.PK Lures - www.pklure.comWebsite - www.jmopodcast.comFacebook - https://www.facebook.com/JMOFishingPodcastInstagram - https://www.instagram.com/the_jmopodcast/

321. Expert Advice on Genetic Testing, Cancer Prevention & Care Disparities with Dr. Rachel Brem Dr. Rachel Brem is back to discuss genetic testing for breast cancer risk, systemic issues within the medical establishment, guidance for those with dense breasts, and practical advice on MRI and mammograms. Plus, we'll hear some of the heartfelt and inspiring messages you've left us since you learned of Amanda's diagnosis.  Discover:  -The shocking statistic about who is most susceptible to breast cancer; -Why every doctor has a bias and what to do about it; -The truth about “overdiagnosis”; and  -How to get genetic testing and what to do with the information you receive. On Dr. Rachel Brem: Dr. Rachel Brem is the author of No Longer Radical: Understanding Mastectomies and Choosing the Breast Cancer Care That's Right For You. Dr. Brem is an internationally known breast cancer expert who has been instrumental in developing and implementing new technologies to improve breast cancer detection. She is Professor and Director of Breast Imaging and Intervention at George Washington University, Vice Chairman of the Department of Radiology, and Chief Medical Advisor and Cofounder of the Brem Foundation. She is a Fellow of the American College of Radiology and the Society of Breast Imaging. Find our first episode with Dr. Brem here: 320. Early Detection, Mammograms & Breast Cancer Care with Dr. Rachel Brem To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

320. Early Detection, Mammograms & Breast Cancer Care with Dr. Rachel Brem Amanda shares an update on her recovery from breast cancer. Then, renowned breast cancer expert, Dr. Rachel Brem, joins the conversation to discuss the critical importance of early detection, breast density's impact on mammography, and when we need additional screenings.  Discover:  -The differing guidance on screenings and the truth about how often you should actually get screened for cancer; -Advice on what to say to your doctors to make sure that you get the screening you need and so that they can be covered under insurance; and -How to learn how dense your breasts are and what to do with that information.  On Dr. Rachel Brem: Dr. Rachel Brem is the author of No Longer Radical: Understanding Mastectomies and Choosing the Breast Cancer Care That's Right For You. Dr. Brem is an internationally known breast cancer expert who has been instrumental in developing and implementing new technologies to improve breast cancer detection. She is Professor and Director of Breast Imaging and Intervention at George Washington University, Vice Chairman of the Department of Radiology, and Chief Medical Advisor and Cofounder of the Brem Foundation. She is a Fellow of the American College of Radiology and the Society of Breast Imaging. Find more resources at The Brem Foundation Website: https://www.bremfoundation.org/  Check out Dr. Brem's Book, No Longer Radical: https://www.nolongerradical.com/ To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

Thema: 11.Frauenmord in Österreich seit Jahresbeginn

Thema: 11.Frauenmord in Österreich seit Jahresbeginn

Bunnsregerung seggt ja to EU-Bitreden vun de Ukraine, al Vörutsettens sünd inlööst +++ Groten Slag gegen Verbreken in´t Internet schafft +++ Nordkorea schickt Ballons mit Schiet un Dreck na Südkorea +++ Brem`sche Börgerschaft besnackt sik över Gewat an Schoolen +++ Tall vun Minschen, de en düütschen Staatsbörger warrn will in Neddersassen 2023 op Höchststand +++ Dat Weer

In a small town in Kapakka, two drunks find an empty tavern, and don't explore why it's abandoned since the entire stock of drinkables is available to them. But then it turns into adventure when they shake their blurry heads upon the unexpected arrival of some dangerous figures. Featuring characters Trest & Brem. Learn more about your ad choices. Visit megaphone.fm/adchoices

In a small town in Kapakka, two drunks find an empty tavern, and don't explore why it's abandoned since the entire stock of drinkables is available to them. But then it turns into adventure when they shake their blurry heads upon the unexpected arrival of some dangerous figures. Featuring characters Trest & Brem. Learn more about your ad choices. Visit megaphone.fm/adchoices

On this episode of Innovate and Elevate, Sharon is joined by Dr. Rachel Brem. Dr. Brem is board-certified in Diagnostic Radiology. She is a Professor of Radiology, the Vice Chair of Radiology, and Director of Breast Imaging & Intervention at The George Washington University School of Medicine & Health Sciences.In this conversation, Dr. Brem shares how to understand your risk for breast cancer and her recommended imaging strategy for those with dense breast tissue. She also emphasizes the importance of co-creating a personalized healthcare plan with a doctor that suits your needs. Note that other risk factors may influence your individual situation. For a comprehensive understanding, explore additional resources at breastcancer.org/risk/risk-factors. Cancer in a dense breast is exponentially more difficult to detect in a mammogram, which is why Dr. Brem is a strong advocate for breast ultrasound and/or MRI. In fact, breast imaging specialists can find 25% more cancerous cells with ultrasound screening in women with dense breasts than they can with mammography. Dr. Brem doesn't believe in a one-size-fits-all breast healthcare approach. Instead, she urges women to get the knowledge they need to make the right choices for their health and find a doctor that can tailor a plan for their unique needs. Finally, Dr. Brem shares her hope in the technologies currently in development to help detect cancer before imaging, such as liquid biopsy and breath analysis. Connect with SharonConnect with Sharon on LinkedIn: Sharon KedarLearn more about Innovate and Elevate innovateandelevatepodcast.comSubscribe to Innovate and Elevate on YouTubeJoin the newsletter to receive the latest episodes in your inbox: Innovate and Elevate NewsletterConnect with Dr. Rachel BremConnect with Dr. Rachel Brem on LinkedIn: Dr. Rachel BremAdditional ResourcesNo Longer Radical by Dr. Rachel Brem and Dr. Christy TealBrem Foundation to Defeat Breast CancerCheckMate by The Brem FoundationTyrer-Cuzick Risk Assessment CalculatorBreast Cancer Risk Assessment Tool (The Gail Model)GlossaryProphylactic mastectomy: A prophylactic mastectomy is surgery to remove one or both breasts to lower the chances of getting breast cancer.BRCA mutation: A BRCA mutation is a mutation in either of the BRCA1 and BRCA2 genes, which are tumor suppressor genes. Harmful mutations in these genes may produce a hereditary breast–ovarian cancer syndrome. Liquid biopsy: A liquid biopsy is a test that checks for signs of diseases by analyzing a small sample...

In this episode, we sit down with Amanda Brem, founder of the Brem Method and former D-1 athlete turned personal trainer. Throughout our conversation, Amanda underscores the importance of aligning goals with core values, pushing past comfort zones, and sharing meaningful insights as an entrepreneur. She highlights her approach to teaching and business building, emphasizing the power of providing valuable free content and developing systems tailored to the needs of her clients and students. As Amanda shares her journey from resistance to embracing entrepreneurship, we delve into her set-it-and-forget-it philosophy for big goals, mental fitness support for students, and the synergy between good business decisions and positive bottom-line impact. ABOUT AMANDAAmanda Brem is the founder of The Brem Method. She is a former D1 athlete and personal trainer that, after scoring in the 97% percentile on her MCAT, realized she didn't actually want to go to medical school. Instead, she wanted to teach others while making med school more accessible to underserved students and those who struggle with test taking. She is also a huge science nerd, Harry Potter fan, and avid skier.LINKS & RESOURCES- Visit The Brem Method's Website- Subscribe to The Brem Method's YouTube channel- Connect with Amanda on LinkedIn

Han føler seg ikke helt hjemme i MGP-sirkuset, advokat og gothminister Bjørn A. Brem. Det til tross: dette kan gå hele veien i lørdagens finale for her har GOTHMINISTER laga en earworm som både jeg og flere kolleger har gått og smånynna på i ukevis.Ja, det er mye MGP om dagen og bra er det! Alle de rock/metal-relaterte innslagene er jo perfekte gjester i Gammal Maiden. Her skal det handle om det å være annerledes og skille seg litt ut, på godt og vondt. Det blir jo ikke godt før det har vært litt vondt, må vite. Det skal handle om horror, industriell metal, Rammstein, Seigmen, Clawfinger og Oomph!Og det skal handle om bæsj og spy ... For her leverer goth-statsråden en turnéhistorie av de sjeldne, HA-HA! Stikkord: Nightliner, motorvei, tømming, dass, kloakk, supportband. Ikke for sarte sjeler denne.

Hosts Mark Mori and Tori Rodriguez welcome Bettie's nephew (and Goldie's son) Ron Brem to the show for some amazing show and tell and cool stories!

„Snažím se vždy spojit dva proudy, a to chodce a dopravu. Takže se staví pro auta, ale zároveň musíme stavět pro lidi, protože ti jsou pro Prahu něco jako rodinné stříbro. A samozřejmě, musíme podporovat i cyklisty,“ říká o budoucnosti hlavního města architekt a urbanista Petr Hlaváček, náměstek pražského primátora za STAN.

„Snažím se vždy spojit dva proudy, a to chodce a dopravu. Takže se staví pro auta, ale zároveň musíme stavět pro lidi, protože ti jsou pro Prahu něco jako rodinné stříbro. A samozřejmě, musíme podporovat i cyklisty,“ říká o budoucnosti hlavního města architekt a urbanista Petr Hlaváček, náměstek pražského primátora za STAN.Všechny díly podcastu Hovory můžete pohodlně poslouchat v mobilní aplikaci mujRozhlas pro Android a iOS nebo na webu mujRozhlas.cz.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/NAX865. CME/MOC/AAPA credit will be available until December 16, 2024.Shattering the Barriers to Glioblastoma Care: Revolutionary Advances With Innovative Technologies and Modern Systemic Approaches In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and American Brain Tumor Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Blue Earth Diagnostics and Novocure, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerSteven Brem, MD, has no financial interests/relationships or affiliations in relation to this activity.Faculty/PlannerManmeet S. Ahluwalia, MD, MBA, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AnHeart Therapeutics; Apollomics, Inc.; Autem Therapeutics; Bayer Corporation; Bugworks; Cairn Therapeutics; Caris Life Sciences; Celularity, Inc.; GSK; GT Medical Technologies; Insightec; Janssen Pharmaceuticals, Inc.; Kiyatec Inc.; Modifi Bio; NH TherAguix; Novocure, Inc.; Nuvation Bio, Inc.; Prelude Therapeutics; Pyramid Biosciences; Sumitomo Dainippon Pharma Oncology; The Menarini Group; Tocagen Inc.; Varian Medical Systems, Inc.; ViewRay Technologies, Inc.; Voyager Therapeutics, Inc.; and Xoft, a subsidiary of iCAD, Inc.Grant/Research Support from Seagen Inc.Stock Shareholder in CytoDyn Inc.; MedInnovate Advisors LLC; and MimiVax, LLC.Faculty/PlannerMichelle Kim, MD, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from Blue Earth Diagnostics.Patient/PlannerJB Bird has no financial interests/relationships or affiliations in relation to this activity.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/NAX865. CME/MOC/AAPA credit will be available until December 16, 2024.Shattering the Barriers to Glioblastoma Care: Revolutionary Advances With Innovative Technologies and Modern Systemic Approaches In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and American Brain Tumor Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Blue Earth Diagnostics and Novocure, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerSteven Brem, MD, has no financial interests/relationships or affiliations in relation to this activity.Faculty/PlannerManmeet S. Ahluwalia, MD, MBA, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AnHeart Therapeutics; Apollomics, Inc.; Autem Therapeutics; Bayer Corporation; Bugworks; Cairn Therapeutics; Caris Life Sciences; Celularity, Inc.; GSK; GT Medical Technologies; Insightec; Janssen Pharmaceuticals, Inc.; Kiyatec Inc.; Modifi Bio; NH TherAguix; Novocure, Inc.; Nuvation Bio, Inc.; Prelude Therapeutics; Pyramid Biosciences; Sumitomo Dainippon Pharma Oncology; The Menarini Group; Tocagen Inc.; Varian Medical Systems, Inc.; ViewRay Technologies, Inc.; Voyager Therapeutics, Inc.; and Xoft, a subsidiary of iCAD, Inc.Grant/Research Support from Seagen Inc.Stock Shareholder in CytoDyn Inc.; MedInnovate Advisors LLC; and MimiVax, LLC.Faculty/PlannerMichelle Kim, MD, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from Blue Earth Diagnostics.Patient/PlannerJB Bird has no financial interests/relationships or affiliations in relation to this activity.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/NAX865. CME/MOC/AAPA credit will be available until December 16, 2024.Shattering the Barriers to Glioblastoma Care: Revolutionary Advances With Innovative Technologies and Modern Systemic Approaches In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and American Brain Tumor Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Blue Earth Diagnostics and Novocure, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerSteven Brem, MD, has no financial interests/relationships or affiliations in relation to this activity.Faculty/PlannerManmeet S. Ahluwalia, MD, MBA, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AnHeart Therapeutics; Apollomics, Inc.; Autem Therapeutics; Bayer Corporation; Bugworks; Cairn Therapeutics; Caris Life Sciences; Celularity, Inc.; GSK; GT Medical Technologies; Insightec; Janssen Pharmaceuticals, Inc.; Kiyatec Inc.; Modifi Bio; NH TherAguix; Novocure, Inc.; Nuvation Bio, Inc.; Prelude Therapeutics; Pyramid Biosciences; Sumitomo Dainippon Pharma Oncology; The Menarini Group; Tocagen Inc.; Varian Medical Systems, Inc.; ViewRay Technologies, Inc.; Voyager Therapeutics, Inc.; and Xoft, a subsidiary of iCAD, Inc.Grant/Research Support from Seagen Inc.Stock Shareholder in CytoDyn Inc.; MedInnovate Advisors LLC; and MimiVax, LLC.Faculty/PlannerMichelle Kim, MD, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from Blue Earth Diagnostics.Patient/PlannerJB Bird has no financial interests/relationships or affiliations in relation to this activity.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/NAX865. CME/MOC/AAPA credit will be available until December 16, 2024.Shattering the Barriers to Glioblastoma Care: Revolutionary Advances With Innovative Technologies and Modern Systemic Approaches In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and American Brain Tumor Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Blue Earth Diagnostics and Novocure, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerSteven Brem, MD, has no financial interests/relationships or affiliations in relation to this activity.Faculty/PlannerManmeet S. Ahluwalia, MD, MBA, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AnHeart Therapeutics; Apollomics, Inc.; Autem Therapeutics; Bayer Corporation; Bugworks; Cairn Therapeutics; Caris Life Sciences; Celularity, Inc.; GSK; GT Medical Technologies; Insightec; Janssen Pharmaceuticals, Inc.; Kiyatec Inc.; Modifi Bio; NH TherAguix; Novocure, Inc.; Nuvation Bio, Inc.; Prelude Therapeutics; Pyramid Biosciences; Sumitomo Dainippon Pharma Oncology; The Menarini Group; Tocagen Inc.; Varian Medical Systems, Inc.; ViewRay Technologies, Inc.; Voyager Therapeutics, Inc.; and Xoft, a subsidiary of iCAD, Inc.Grant/Research Support from Seagen Inc.Stock Shareholder in CytoDyn Inc.; MedInnovate Advisors LLC; and MimiVax, LLC.Faculty/PlannerMichelle Kim, MD, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from Blue Earth Diagnostics.Patient/PlannerJB Bird has no financial interests/relationships or affiliations in relation to this activity.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/NAX865. CME/MOC/AAPA credit will be available until December 16, 2024.Shattering the Barriers to Glioblastoma Care: Revolutionary Advances With Innovative Technologies and Modern Systemic Approaches In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and American Brain Tumor Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Blue Earth Diagnostics and Novocure, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerSteven Brem, MD, has no financial interests/relationships or affiliations in relation to this activity.Faculty/PlannerManmeet S. Ahluwalia, MD, MBA, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AnHeart Therapeutics; Apollomics, Inc.; Autem Therapeutics; Bayer Corporation; Bugworks; Cairn Therapeutics; Caris Life Sciences; Celularity, Inc.; GSK; GT Medical Technologies; Insightec; Janssen Pharmaceuticals, Inc.; Kiyatec Inc.; Modifi Bio; NH TherAguix; Novocure, Inc.; Nuvation Bio, Inc.; Prelude Therapeutics; Pyramid Biosciences; Sumitomo Dainippon Pharma Oncology; The Menarini Group; Tocagen Inc.; Varian Medical Systems, Inc.; ViewRay Technologies, Inc.; Voyager Therapeutics, Inc.; and Xoft, a subsidiary of iCAD, Inc.Grant/Research Support from Seagen Inc.Stock Shareholder in CytoDyn Inc.; MedInnovate Advisors LLC; and MimiVax, LLC.Faculty/PlannerMichelle Kim, MD, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from Blue Earth Diagnostics.Patient/PlannerJB Bird has no financial interests/relationships or affiliations in relation to this activity.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/NAX865. CME/MOC/AAPA credit will be available until December 16, 2024.Shattering the Barriers to Glioblastoma Care: Revolutionary Advances With Innovative Technologies and Modern Systemic Approaches In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and American Brain Tumor Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Blue Earth Diagnostics and Novocure, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerSteven Brem, MD, has no financial interests/relationships or affiliations in relation to this activity.Faculty/PlannerManmeet S. Ahluwalia, MD, MBA, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AnHeart Therapeutics; Apollomics, Inc.; Autem Therapeutics; Bayer Corporation; Bugworks; Cairn Therapeutics; Caris Life Sciences; Celularity, Inc.; GSK; GT Medical Technologies; Insightec; Janssen Pharmaceuticals, Inc.; Kiyatec Inc.; Modifi Bio; NH TherAguix; Novocure, Inc.; Nuvation Bio, Inc.; Prelude Therapeutics; Pyramid Biosciences; Sumitomo Dainippon Pharma Oncology; The Menarini Group; Tocagen Inc.; Varian Medical Systems, Inc.; ViewRay Technologies, Inc.; Voyager Therapeutics, Inc.; and Xoft, a subsidiary of iCAD, Inc.Grant/Research Support from Seagen Inc.Stock Shareholder in CytoDyn Inc.; MedInnovate Advisors LLC; and MimiVax, LLC.Faculty/PlannerMichelle Kim, MD, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from Blue Earth Diagnostics.Patient/PlannerJB Bird has no financial interests/relationships or affiliations in relation to this activity.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Programa completo de 'Julia en la Onda' con Julia Otero: Guillem Zaragoza, Roger de Gràcia y Aneyma León abren la Mesa de Redacción. José Luis Gallego ofrece consejos de reciclaje y Clara Jiménez Cruz trae su Maldita Hemeroteca. David Martos comenta las novedades del mundo del cine en el Territorio Kinótico, y charlamos de moda con la diseñadora Pepa Salazar. Javier Traité y Consuelo Sanz de Bremón presentan su última obra "El olor de la Edad Media", y en el Gabinete Asun Salvador, Julián Casanova, Carolina Bescansa y Fernado Iwasaki debaten sobre las herencias. 

El historiador Javier Traité y la entomóloga Consuelo Sanz de Bremón han publicado "El olor de la Edad Media: higiene y salud en la Europa Medieval", una larga investigación que desmonta falsas creencias acerca de este período histórico tan desconocido. 

Today, we talk to Christine Teal, MD, the Chief of Breast Surgery at The George Washington University Hospital, and Rachel Brem, MD, vice chair of Radiology and director of the Breast Imaging & Intervention Center. They are the authors of “No Longer Radical: Understanding Mastectomies and Choosing the Breast Cancer Care That's Right For You.” Published in May 2023, it's a life-saving and empowering guide to understanding breast cancer detection, prevention, and treatment options. Dr. Teal and her colleagues have developed a cutting-edge, holistic, patient-focused Breast Care Center that integrates complementary medicine with the latest technology and surgical innovations. Dr. Brem is an internationally known breast cancer expert who has been instrumental in developing and implementing new technologies to improve breast cancer detection. She is also deeply motivated to eliminate health care disparities. ◘ Related Content: No Longer Radical: Understanding Mastectomies and Choosing the Breast Cancer Care That's Right For You amzn.to/3JdXtyP ◘ Transcript: amzn.to/3JdXtyP ◘ This podcast features the song “Follow Your Dreams” (freemusicarchive.org/music/Scott_Ho…ur_Dreams_1918) by Scott Holmes, available under a Creative Commons Attribution-Noncommercial (01https://creativecommons.org/licenses/by-nc/4.0/) license. ◘ Disclaimer: The content and information shared in GW Integrative Medicine is for educational purposes only and should not be taken as medical advice. The views and opinions expressed in GW Integrative Medicine represent the opinions of the host(s) and their guest(s). For medical advice, diagnosis, and/or treatment, please consult a medical professional.

Kabarnya tahun depan untuk produk yang belum bersertifikat halal akan dikenakan sanksi.

This week Jack Brem Smith, an Employment Law Attorney at Smith Law Firm describes his career path and current role. He talks about: His background Why he got into law Why he chose to be an attorney Why he chose employment law Different options within law What he likes about being a trial attorney Extracurriculars he did to prepare him for his career His career steps after law school How having a family changed his career path What a typical week is like His main roles and responsibilities The most common needs of his clients Examples of services he provides Typical hours of the role Expectations around developing your own practice as a new lawyer How he built his own practice the nature of the work Percent of time alone vs w/ ppl What he likes about the role and finds challenging Typical steps for moving up Important characteristics to be successful Advice

In the latest episode of The HemOnc Pulse, podcast host Chadi Nabhan, MD, MBA, FACP, talks with Elizabeth Brem, MD, Clinical Associate Professor in the School of Medicine at the University of California, Irvine, off the heels of the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition. Dr. Brem discusses which chronic lymphocytic leukemia (CLL) abstracts from ASH 2022 cannot be ignored, the latest news in Richter's transformation, and why she is moving away from ibrutinib in her own clinical practice.

Go online to PeerView.com/YNM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Innovative science is poised to transform glioblastoma management by offering the opportunity to enhance conventional management through the use of newer modalities, including tumor treating fields (TTFields) and efficacious systemic therapies. These novel options have been incorporated into clinical practice guidelines and are driving improved outcomes for patients with newly diagnosed and recurrent disease. The current challenge is how best to use these modalities as part of sequential and highly effective combination strategies across glioblastoma treatment settings. In a new “Seminars & Practicum” event from PeerView and the American Brain Tumor Association (ABTA), expert panelists will link current science to practical decisions that can help clinicians “set their sights” on achieving improved outcomes in glioblastoma. Throughout the lecture and case-based segments, the experts will provide context for the real-world impact of glioblastoma, focus on the latest efficacy and safety data on TTFields, discuss TTFields delivery considerations, and address the integration of targeted and biomarker-guided therapies into glioblastoma management. This program will also feature a patient's perspective on how newer modalities have impacted his therapeutic journey. Set your sights on better outcomes in glioblastoma, and join us for this important educational activity! Upon completion of this activity, participants should be better able to: Articulate the roles, mechanisms of action, and key clinical evidence on novel guideline-recommended treatment options, including TTFields, multikinase inhibitors, and gene-directed therapies (eg, TRK inhibitors), for patients with newly diagnosed (post-radiation) or recurrent glioblastoma; Consider clinical trials evaluating innovative treatment strategies as standard therapeutic options for patients with newly diagnosed or recurrent glioblastoma, based on an understanding of their clinical rationales, efficacy, and safety; Develop contemporary, personalized management plans for patients with glioblastoma that incorporate novel therapeutics, expert recommendations, and individual patient needs and preferences; andEmploy proactive, team-based strategies to address practical aspects, including adverse event management, patient education, and disparities in clinical care and research, associated with using novel therapeutics for patients with glioblastoma

Go online to PeerView.com/YNM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Innovative science is poised to transform glioblastoma management by offering the opportunity to enhance conventional management through the use of newer modalities, including tumor treating fields (TTFields) and efficacious systemic therapies. These novel options have been incorporated into clinical practice guidelines and are driving improved outcomes for patients with newly diagnosed and recurrent disease. The current challenge is how best to use these modalities as part of sequential and highly effective combination strategies across glioblastoma treatment settings. In a new “Seminars & Practicum” event from PeerView and the American Brain Tumor Association (ABTA), expert panelists will link current science to practical decisions that can help clinicians “set their sights” on achieving improved outcomes in glioblastoma. Throughout the lecture and case-based segments, the experts will provide context for the real-world impact of glioblastoma, focus on the latest efficacy and safety data on TTFields, discuss TTFields delivery considerations, and address the integration of targeted and biomarker-guided therapies into glioblastoma management. This program will also feature a patient's perspective on how newer modalities have impacted his therapeutic journey. Set your sights on better outcomes in glioblastoma, and join us for this important educational activity! Upon completion of this activity, participants should be better able to: Articulate the roles, mechanisms of action, and key clinical evidence on novel guideline-recommended treatment options, including TTFields, multikinase inhibitors, and gene-directed therapies (eg, TRK inhibitors), for patients with newly diagnosed (post-radiation) or recurrent glioblastoma; Consider clinical trials evaluating innovative treatment strategies as standard therapeutic options for patients with newly diagnosed or recurrent glioblastoma, based on an understanding of their clinical rationales, efficacy, and safety; Develop contemporary, personalized management plans for patients with glioblastoma that incorporate novel therapeutics, expert recommendations, and individual patient needs and preferences; andEmploy proactive, team-based strategies to address practical aspects, including adverse event management, patient education, and disparities in clinical care and research, associated with using novel therapeutics for patients with glioblastoma

Go online to PeerView.com/YNM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Innovative science is poised to transform glioblastoma management by offering the opportunity to enhance conventional management through the use of newer modalities, including tumor treating fields (TTFields) and efficacious systemic therapies. These novel options have been incorporated into clinical practice guidelines and are driving improved outcomes for patients with newly diagnosed and recurrent disease. The current challenge is how best to use these modalities as part of sequential and highly effective combination strategies across glioblastoma treatment settings. In a new “Seminars & Practicum” event from PeerView and the American Brain Tumor Association (ABTA), expert panelists will link current science to practical decisions that can help clinicians “set their sights” on achieving improved outcomes in glioblastoma. Throughout the lecture and case-based segments, the experts will provide context for the real-world impact of glioblastoma, focus on the latest efficacy and safety data on TTFields, discuss TTFields delivery considerations, and address the integration of targeted and biomarker-guided therapies into glioblastoma management. This program will also feature a patient's perspective on how newer modalities have impacted his therapeutic journey. Set your sights on better outcomes in glioblastoma, and join us for this important educational activity! Upon completion of this activity, participants should be better able to: Articulate the roles, mechanisms of action, and key clinical evidence on novel guideline-recommended treatment options, including TTFields, multikinase inhibitors, and gene-directed therapies (eg, TRK inhibitors), for patients with newly diagnosed (post-radiation) or recurrent glioblastoma; Consider clinical trials evaluating innovative treatment strategies as standard therapeutic options for patients with newly diagnosed or recurrent glioblastoma, based on an understanding of their clinical rationales, efficacy, and safety; Develop contemporary, personalized management plans for patients with glioblastoma that incorporate novel therapeutics, expert recommendations, and individual patient needs and preferences; andEmploy proactive, team-based strategies to address practical aspects, including adverse event management, patient education, and disparities in clinical care and research, associated with using novel therapeutics for patients with glioblastoma

Go online to PeerView.com/YNM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Innovative science is poised to transform glioblastoma management by offering the opportunity to enhance conventional management through the use of newer modalities, including tumor treating fields (TTFields) and efficacious systemic therapies. These novel options have been incorporated into clinical practice guidelines and are driving improved outcomes for patients with newly diagnosed and recurrent disease. The current challenge is how best to use these modalities as part of sequential and highly effective combination strategies across glioblastoma treatment settings. In a new “Seminars & Practicum” event from PeerView and the American Brain Tumor Association (ABTA), expert panelists will link current science to practical decisions that can help clinicians “set their sights” on achieving improved outcomes in glioblastoma. Throughout the lecture and case-based segments, the experts will provide context for the real-world impact of glioblastoma, focus on the latest efficacy and safety data on TTFields, discuss TTFields delivery considerations, and address the integration of targeted and biomarker-guided therapies into glioblastoma management. This program will also feature a patient's perspective on how newer modalities have impacted his therapeutic journey. Set your sights on better outcomes in glioblastoma, and join us for this important educational activity! Upon completion of this activity, participants should be better able to: Articulate the roles, mechanisms of action, and key clinical evidence on novel guideline-recommended treatment options, including TTFields, multikinase inhibitors, and gene-directed therapies (eg, TRK inhibitors), for patients with newly diagnosed (post-radiation) or recurrent glioblastoma; Consider clinical trials evaluating innovative treatment strategies as standard therapeutic options for patients with newly diagnosed or recurrent glioblastoma, based on an understanding of their clinical rationales, efficacy, and safety; Develop contemporary, personalized management plans for patients with glioblastoma that incorporate novel therapeutics, expert recommendations, and individual patient needs and preferences; andEmploy proactive, team-based strategies to address practical aspects, including adverse event management, patient education, and disparities in clinical care and research, associated with using novel therapeutics for patients with glioblastoma

Go online to PeerView.com/YNM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Innovative science is poised to transform glioblastoma management by offering the opportunity to enhance conventional management through the use of newer modalities, including tumor treating fields (TTFields) and efficacious systemic therapies. These novel options have been incorporated into clinical practice guidelines and are driving improved outcomes for patients with newly diagnosed and recurrent disease. The current challenge is how best to use these modalities as part of sequential and highly effective combination strategies across glioblastoma treatment settings. In a new “Seminars & Practicum” event from PeerView and the American Brain Tumor Association (ABTA), expert panelists will link current science to practical decisions that can help clinicians “set their sights” on achieving improved outcomes in glioblastoma. Throughout the lecture and case-based segments, the experts will provide context for the real-world impact of glioblastoma, focus on the latest efficacy and safety data on TTFields, discuss TTFields delivery considerations, and address the integration of targeted and biomarker-guided therapies into glioblastoma management. This program will also feature a patient's perspective on how newer modalities have impacted his therapeutic journey. Set your sights on better outcomes in glioblastoma, and join us for this important educational activity! Upon completion of this activity, participants should be better able to: Articulate the roles, mechanisms of action, and key clinical evidence on novel guideline-recommended treatment options, including TTFields, multikinase inhibitors, and gene-directed therapies (eg, TRK inhibitors), for patients with newly diagnosed (post-radiation) or recurrent glioblastoma; Consider clinical trials evaluating innovative treatment strategies as standard therapeutic options for patients with newly diagnosed or recurrent glioblastoma, based on an understanding of their clinical rationales, efficacy, and safety; Develop contemporary, personalized management plans for patients with glioblastoma that incorporate novel therapeutics, expert recommendations, and individual patient needs and preferences; andEmploy proactive, team-based strategies to address practical aspects, including adverse event management, patient education, and disparities in clinical care and research, associated with using novel therapeutics for patients with glioblastoma

Go online to PeerView.com/YNM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Innovative science is poised to transform glioblastoma management by offering the opportunity to enhance conventional management through the use of newer modalities, including tumor treating fields (TTFields) and efficacious systemic therapies. These novel options have been incorporated into clinical practice guidelines and are driving improved outcomes for patients with newly diagnosed and recurrent disease. The current challenge is how best to use these modalities as part of sequential and highly effective combination strategies across glioblastoma treatment settings. In a new “Seminars & Practicum” event from PeerView and the American Brain Tumor Association (ABTA), expert panelists will link current science to practical decisions that can help clinicians “set their sights” on achieving improved outcomes in glioblastoma. Throughout the lecture and case-based segments, the experts will provide context for the real-world impact of glioblastoma, focus on the latest efficacy and safety data on TTFields, discuss TTFields delivery considerations, and address the integration of targeted and biomarker-guided therapies into glioblastoma management. This program will also feature a patient's perspective on how newer modalities have impacted his therapeutic journey. Set your sights on better outcomes in glioblastoma, and join us for this important educational activity! Upon completion of this activity, participants should be better able to: Articulate the roles, mechanisms of action, and key clinical evidence on novel guideline-recommended treatment options, including TTFields, multikinase inhibitors, and gene-directed therapies (eg, TRK inhibitors), for patients with newly diagnosed (post-radiation) or recurrent glioblastoma; Consider clinical trials evaluating innovative treatment strategies as standard therapeutic options for patients with newly diagnosed or recurrent glioblastoma, based on an understanding of their clinical rationales, efficacy, and safety; Develop contemporary, personalized management plans for patients with glioblastoma that incorporate novel therapeutics, expert recommendations, and individual patient needs and preferences; andEmploy proactive, team-based strategies to address practical aspects, including adverse event management, patient education, and disparities in clinical care and research, associated with using novel therapeutics for patients with glioblastoma

Melanie Brem of ConnectLife on the need for platelets

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2022.11.25.517926v1?rss=1 Authors: Haugg, A., Frei, N., Menghini, M., Stutz, F., Steinegger, S., Roethlisberger, M., Brem, S. Abstract: The Visual Word Form Area (VWFA) is a key region of the brain's reading network and its activation has been shown to be strongly associated with reading skills. Here, for the first time, we investigated whether voluntary regulation of VWFA activity is feasible using real-time fMRI neurofeedback. 40 adults with typical reading skills were instructed to either upregulate (UP group) or downregulate (DOWN group) their own VWFA activity during six neurofeedback training runs. The VWFA target region was individually defined based on a functional localizer task. Before and after training, also regulation runs without feedback ('no-feedback runs') were performed. When comparing the two groups, we found stronger activity across the whole reading network, including the VWFA, for the UP than the DOWN group. Crucially, we observed a significant interaction of group and time (pre, post) for the no-feedback runs: The two groups did not differ in their VWFA activity before neurofeedback training, but the UP group showed significantly stronger activity than the DOWN group after neurofeedback training. Our results indicate that self-regulation of the VWFA activity is feasible and that, once learned, successful self-regulation can even be performed in the absence of feedback. These results are a crucial step toward to development of a potential clinical intervention to improve reading skills in individuals with reading impairments. Copy rights belong to original authors. Visit the link for more info Podcast created by Paper Player, LLC

in der letzten Episode haben wir über den Streit innerhalb der Eurovision Fanclubs berichtet: Der OGAE Song Contest wurde auf Grund der Streitigkeiten abgesagt.  Der russische Superstar, die legendäre Alla Pugatschowa (1997 beim Eurovision mit "Primadonna") hat den Krieg gegen die Ukraine und die Politik Putins scharf kritisiert.Er vertrat Österreich 1980 mit der Band Blue Danube und 1981 als Solo-Künstler beim Eurovision Song Contest: Martin Brem, der sich damals noch Marty nannte. Heute ist er "Head of Global Music Services" bei Red Bull. Er erzählt wie er nach dem ESC zuerst Journalist und dann einer der erfolgreichsten Musik-Manager Europas wurde. Und warum er mit Céline Dion befreundet ist.Brem begann seine Musikkarriere bei verschiedenen Bands und mit 19 veröffentlichte er seine erste Singles. Der ORF engagierte ihn für die Casting-Band Blue Danube, steckte ihn und seine Mitstreiter in Helmut-Lang-Anzüge und auf die Bühne des Song Contests, wo sie 1980 "Du bist Musik" in Den Haag sangen und den 8. Platz belegten.Ein Jahr später fand der Song Contest in Dublin statt.  Nach einem Vorentscheid, in dem der Interpret gesucht wurde und Marty Brem wurde wieder geschickt, diesmal als Solist. Einige Songs wurden für ihn produziert und als Show im ORF ausgestrahlt. "Wenn du da bist" konnte nicht an den Erfolg von "Du bist Musik" anknüpfen, es wurde nur der 17. Platz von 20.Nach vernichtenden Kriterien konzentrierte sich Brem auf das journalistische Schreiben, "Popcorn" und "Musik-Express/Sounds", lieferte 1986 die Singstimme für Niki Lists Film "Müllers Büro" und arbeitete für diverse Plattenlabels. Und lernte Céline Dion als gute Freundin kennen. Ein persönliche Tragödie 2001 führte zu Veränderungen. Zeitgleich veränderte sich die Plattenindustrie und das Musikbusiness (siehe auch die Episode #0323 "Wie funktioniert das Musikbusiness heute? Mit Hannes Tschürtz") - es folgte einem neuer Karrierepfad - die Mode. Ende der 2000erJahre ging es zurück zur Musik. Und er schloss Frieden mit dem Songcontest, denn die OGAE Deutschland lud ihn zu einem Treffen ein und er performte "Wenn du da bist" seit 1981 zum ersten Mal seit 1981 wieder auf einer Bühne.Die Fragen am Schluss fallen etwas kurz aus, denn Martin Brem verfolgt den aktuellen Eurovision Song Contest nicht. Aber die Antwort auf die Frage nach dem Lieblingstitel alles Zeiten ist ungewöhnlich: Nicht Célinie Dions Siegerlied "Ne partez pas sans moi" aus dem Jahr 1988 ist es. Nein, im Gegenteil: Ein Lied, das den letzten Platz belegte, aber wohl der künstlerisch interessanteste Beitrag der 70er Jahre bei Eurovision war: "Heute in Jerusalem", getextet von André Heller und gesungen von Christina Simon, die als Ina Wolf Karriere machen sollte. In der Kleinen Song Contest Geschichte erinnert sich Marco an die Schweizer Teilnehmer Peter, Sue & Marc.

In this episode, host Daniel Arnold talks about Advances in Breast Imaging with Rachel F. Brem, MD, FACR, FSBI, Professor and Vice-Chair, Director, Breast Imaging and Interventional Center, George Washington University.  Dr. Brem talks about her inspiration for becoming a radiologist, her passion to serve, advocate, and educate through The Brem Foundation, and why she seeks novel ways to find solutions for problems. Daniel and Dr. Brem also talk about how she approaches new technologies, and thinking outside the box when it comes to imaging and innovation. Like this episode? We'd love it if you could leave us a five star review! And make sure to subscribe, so you never miss an opportunity to hear from the leaders in radiology. Learn more at radiologyreportpodcast.com.

Katra mēneša vidū ceturdienas vakarā trīs izcilu džeza mūziķu grupas pulcēsies Kultūras pils "Ziemeļblāzma" parkā, lai atskaņotu savas oriģinālprogrammas nesteidzīgā vasaras vakara gaisotnē. Tā būs kolorīta Latvijas pieredzējušāko džeza izpildītājmākslinieku parāde... 14. jūlijā klausītāji varēs baudīt Rihards Lībietis Orchestra, Raimonda Macata kvinteta un diksilenda "Sapņu komanda" sniegumu. Trešdienas "Neatliekamajā sarunā" ar "Sapņu komandas" vadītāju Indriķi Veitneru runājam par diksilenda stilu, spēles un nejaušības elementiem, kā arī džezu toreiz un tagad... Anna Marta Burve: Preses relīzē minēts, ka programmā skan gan diksilenda žanra klasika, gan novatoriski un asprātīgi aranžēti pazīstami mūsdienu ārzemju un latviešu popmūzikas hiti. Ko īsti nozīmē diksilenda žanra klasika, kā tas izpaužas mūzikā un kā tas atšķiras no citiem spēles stiliem?  Diksilends tiek uzskatīts par pirmo senāko džeza stilu, ar ko džezs vispār sākās 20. gadsimta pašā sākumā. Un pašos pamatos diksilends attīstījās no pūtēju orķestra, tāpēc tur ir pūšamie instrumenti - klarnete, kornete un trombons. Galvenais princips, kas diksilendam ir svarīgs - ka tā ir kolektīvā improvizācija. Šie trīs instrumenti, cits caur citu viens otram piebalsojot, apspēlējot melodiju, kur trompete ir galvenā, bet klarnete apspēlē augšējo reģistru, trombons pievelk kontrapunktu vai pretmelodiju, veido harmoniju. Veidojas trīs skaņas pa vertikāli, akords, līdz ar to tiek radīta ļoti dzīva un dzīvespriecīga mūzika. Tā ir mūzika, kas skanēja ballītēs un ielu parādēs, galvenokārt jau ielu parādēs, un tādā veidā radās džezs, tā arī radās improvizācija. Līdz ar to diksilenda žanra klasika ir Amerikas 20. un 30. gadu populārā mūzika. Slavenākais pārstāvis ir Lūiss Ārmstrongs, kurš savulaik uzstājās ar sastāviem "Hot Five" un "Hot Seven". Vai diksilends bija sava veida afroamerikāņu atsvabināšanās no verdzības, un tādā veidā viņi šo jauno brīvību it kā svinēja caur šo brīvo improvizāciju? Kaut kādā mērā šodien tā var teikt. Bet tā realitāte bija daudz vienkāršāka - lielākā daļa no viņiem nepazina notis, līdz ar to tā patiesībā bija spēlēšana no galvas vai pēc dzirdes, un tādā gadījumā kādā brīdī to melodiju mūziķis sāk variēt. Un, tā kā pats galvenais Āfrikas mūzikas pamats ir ritms, ritmiskā pulsācija, tad tas savijās viss kopā ar Rietumeiropas mūzikas pamatprincipiem - skaņdarbu formu, piemēram, kas savukārt nāk no Rietumeiropas, un tad kopā tas tā saveidojās. Kā jūs savā "Sapņu komandā" veidojat šo procesu? Vai arī jums ir līdzīgi, ka ir pilnīga brīvība, vai tas process tomēr ir citādāks un mūsdienīgāks? Nē, nē, tieši tieši tā tas arī notiek, tas ir tas ir iemesls, kāpēc mēs to spēlējam. Jo šī mūzika ir ļoti pozitīva, un tas pats galvenais ir tiešām tas mirklis. Tev faktiski momentā ir jāreaģē uz to, ko dara citi kolēģi, un tas katrreiz notiek savādāk. Es to drīzāk salīdzinātu ar ļoti aizraujošu sarunu draugu pulkā par kādu absolūti visiem interesējošu tēmu. Vai arī savā ziņā to var salīdzināt arī ar komandas spēli, piemēram, basketbolu. Tas ir foršs basketbols, ka tu mētā to bumbu, tev jābūt visu laiku gatavam, ka kāds tev pēkšņi metīs bumbu, tev jābūt gatavam mest to pa grozu un saspēlēt ar pārējiem. Tas ir tieši tik jauki. Un tas viss ir labā ritmā, tā ir dejojama mūzika. Cilvēki dejo pie šīs mūzikas. Vai gadījumā nav grūti apstāties? Respektīvi, ja jūs visu laiku to bumbu mētājat, jums kā mūziķiem ir interesanti turpināt, bet vienā brīdī klausītāju dzirde ir jāatpūtina. Jebkura spēle kādreiz beidzas, un kaut kāda forma tomēr šeit pastāv. Protams, ka noteikumi ikr - nav jau tā, ka tas ir pilnīgi brīvs pasākums.Bet diksilenda kolektīvās muzicēšanas princips ir ļoti svarīgs džeza mūzikā vispār, un tieši tāpēc arī akadēmijā, it īpaši pašos pirmajos kursos, es pievēršu diezgan lielu uzmanību šim pasākumam, jo profesionālam mūziķim ir jāvar spēlēt pēc dzirdes. Jo arī vēlākajos stilos šis princips ir ārkārtīgi klātesošs, piemēram, frīdžezs pēc būtības ne ar ko daudz neatšķiras, tikai to, ka tas ir vēl brīvāks, atonālāks, un arī forma tiek veidota uz vietas. Šeit mums ir konkrēts skaņdarbs ar konkrētu taktu skaitu, bet princips ir tas pats. Domājot par to kolektīvo improvizāciju - mēs zinām, ka arī džeza mūzikā ir soloizgājieni. Vai diksilends līdz ar Lūisu Ārmstrongu pieļāva arī to, ka ir šie soliņi?  Jā, protams, tur jau tā lieta, ka sākumā jau tā bija vienkārši kolektīva spēlēšana, jo tanī laikā jau neviens nemaz nezināja tādu vārdu kā improvizēšana.Viņi vienkārši spēlēja pēc dzirdes. Solo spēlēšana, individuālā improvizēšana attīstījās vēlāk. Lūiss Ārmstrongs tāpēc arī tiek uzskatīts par vienu no lielākajiem džeza ģēnijiem, jo, pateicoties viņa ģenialitātei kā mūziķim, viņš bija paraugs pārējiem, un patiesībā viņš to lielā mērā aizsāka un parādīja, ka var arī spēlēt solo. Ir interesanti novērot, kā tas transformējas: ka sākumā diksilends ir kā kolektīvā muzicēšana, pēc tam ienāk Lūiss Ārmstrongs ar saviem solo un beigās jūs pieminat arī frīdžezu. Cik ļoti tās tradīcijas ir savijušās! Jā, jā, tieši tā - tās visas ir klātesošas. Ļoti interesanti, ka arī klausoties ļoti modernus stilus, ja mūziķis ir patiešām profesionāls un kompetents, viņa spēlē jūs varat dzirdēt visu džeza vēsturi. Kaut kur tas parādīsies. To varētu salīdzināt ar spēju pielietot dažādus izteiksmes līdzekļus savā radošajā izpausmē. Vairāk un plašāk - ierakstā. *** DIKSILENDS "SAPŅU KOMANDA" Indriķis Veitners (klarnete un saksofons) Madars Kalniņš (taustiņinstrumenti). Normunds Piesis (trompete) Lauris Amantovs (trombons) Andris Grunte (kontrabass) Krišjānis Bremšs (sitaminstrumenti) Bruno Priekulis (bandžo) Spēlfilmas "Sapņu komanda 1935" skaņu celiņa veidošanai 2013. gadā tika izveidots raksturīgs 1930. gadu džeza ansambļa - diksilenda sastāvs, kurā tika pieaicināti vadošie Latvijas džeza mūziķi. Ieraksta procesā pavisam negaidīti jau no pirmajām skaņām izveidojās jauns, brīnišķīgi un oriģināli skanošs džeza kolektīvs, kura lielisko veikumu iespējams dzirdēt filmā.   Labi iesāktais tiek turpināts, uzstājoties ar vairākām koncertprogrammām: "Ceļojums uz uz Diksi-lendu", "Ceļojums uz Diksi-lendu – 2" (kopā ar dziedātājiem Kristīni Prauliņu, Nauri Puntuli, kā arī vokālo grupu "Neaizmirstulītes"), "Trauksmainie divdesmitie". Latvijas džeza sākumi no "Šņāci, Minna" līdz "Vecajam ratiņam" – kopā ar dziedātāju Normundu Rutuli. Koncertprogramma "Ceļojums uz uz Diksi-lendu" veltīta tradicionālā džeza stila - diksilenda stilistikai, taču radoši un inovatīvi izmantojot šī tradicionālā džeza sastāva iespējas. Programmā skan skan gan diksilenda žanra klasika, gan novatoriski un asprātīgi aranžēti pazīstami mūsdienu ārzemju un latviešu popmūzikas hiti. Savukārt "Trauksmainie divdesmitie" ir izzinoša, jautra un dinamiska koncertprogramma, kas klausītāju aizved Latvijas džeza pirmsākumos 1920. gados, kad skanēja čarlstons, cilvēki dejoja neskaitāmās ballēs, bet džezs neatturami sāka savu uzvaras gājienu. Programmā skan lielākie to gadu grāvēji autentiskā izpildījumā, kopā ar eleganto Normundu Rutuli! "Sapņu komanda" ir uzstājusies labākajos Latvijas džeza festivālos, regulāri koncertē gan publiskos, gan korporatīvos pasākumos, kā arī Rīgas un Latvijas džeza klubos. Kopā ar diksilendu dažādās programmās uzstājas dziedātāji Kristīne Prauliņa, Nauris Puntulis, Normunds Rutulis kā arī vokālā grupa "Neaizmirstulītes", radot krāsainu un dinamisku priekšnesumu. Ieskaņots arī pirmais albums - Sonny Boy. Skaņdarbi no grupas albuma iekļauti 2018. gada Latvijas džeza izlases CD starptautiskājā mūzikas izstādē WOMEX. Par mūziķiem: Grupas sastāvā apvienojušies labi pazīstami Latvijas džeza mūzikas profesionāļi ar stāžu un pieredzi daudzskaitlīgos sastāvos un visdažādākajos projektos. Diksilenda vadītājs, klarnetists un saksofonists Indriķis Veitners vienlaicīgi ir arī pasniedzējs un džeza katedras vadītājs JVLMA, kā arī nodarbojas ar Latvijas džeza vēstures pētniecību.  Pianists, komponists un aranžētājs Madars Kalniņš ir labi pazīstams Latvijas džeza mūziķis, kurš arī ir pasniedzējs JVLMA džeza katedrā un patlaban veic sava soloalbuma ierakstu. Viens no labākajiem Latvijas džeza trompetistiem Normunds Piesis kopā ar pieredzējušo džeza trombonistu Lauri Amantovu, bigbenda Mirage Jazz orchestra vadītāju, veido spēcīgu metāla pūšamo instrumentu tandēmu. Savukārt pazīstamais latviešu kontrabasists Andris Grunte, viens no labākajiem jaunās paaudzes bundziniekiem Krišjānis Bremšs un bandžo spēlētājs Bruno Priekulis kopā rada robustu, svingojošu ritma grupas sniegumu, veidojot raksturīgo un neatkārtojamo “Sapņu komandas” skanējumu.

Bluder, Roti Manis dari Kota Gadis Oleh. Deena Noor (Kontributor Tetap NarasiPost.Com) Voice over talent: Maya Rohmah NarasiPost.Com-Apakah Anda penyuka roti? Pernah makan bluder (bukan blunder lho, ya!)? Jika belum, cobalah nikmati roti jadul yang satu ini. Sekali mencoba, yakin akan menambah lagi, lagi, dan lagi. Hehehe… Roti bluder adalah kuliner ikonik dari kota Gadis. Wah, di mana itu? Kota Gadis adalah julukan bagi kota Madiun yang merupakan singkatan dari Perdagangan, Pendidikan, dan Perindustrian. Nah, roti bluder ini menjadi salah satu penganan yang identik dengan kota Madiun selain Brem dan Pecel. Karena itulah ia sering dicari untuk dinikmati atau pun sebagai oleh-oleh bila berkunjung ke kota ini. Menurut sejarahnya, roti bluder sudah ada sejak zaman penjajahan Belanda. Ia dibawa oleh orang-orang Eropa ke Indonesia. Roti ini biasanya menjadi santapan wajib tentara Belanda. Bisa dikatakan bahwa roti bluder merupakan peninggalan masa Belanda yang kemudian berkembang menyesuaikan lidah rakyat Indonesia. Naskah selengkapnya: https://narasipost.com/2022/05/21/bluder-roti-manis-dari-kota-gadis/ Terimakasih buat kalian yang sudah mendengarkan podcast ini, Follow us on: instagram: http://instagram.com/narasipost Facebook: https://www.facebook.com/narasi.post.9 Fanpage: Https://www.facebook.com/pg/narasipostmedia/posts/ Twitter: Http://twitter.com/narasipost

avec Cybèle de Brem, co-directrice  de la Fondation Lemarchand et Sylvie Faye fondatrice de l'association Multicolors.

Go online to PeerView.com/EWB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How do your colleagues incorporate the latest research and guideline recommendations into the clinical management of patients with glioblastoma multiforme (GBM)? With a median overall survival of only 15 months, GBM has long presented a challenge to the multidisciplinary management team. To maximize patient survival and QOL, clinicians who treat patients with this complex, diverse, fast-growing, and aggressive brain tumor must be prepared to quickly create personalized management plans that incorporate several new modalities, including tumor treating fields (TTFields) and efficacious systemic therapies, as well as clinical trial–based options. In a new event from PeerView and the American Brain Tumor Association (ABTA), an expert panel will review the latest efficacy and safety data on multimodal GBM treatments, along with a clear rationale for selecting guideline-recommended treatments and strategies for incorporating these advances into clinical practice. This case-based activity has been designed to help clinicians hone their informed decision-making skills and personalize management plans and for the benefit of patients with GBM in a variety of settings. Upon completion of this CE activity, participants will be able to: Describe the biologic rationale and latest clinical evidence for the use of guideline-recommended treatment strategies, such as TTFields and multikinase and TRK inhibitors, for patients with newly diagnosed and recurrent GBM, Identify patients with GBM who may benefit from participation in a clinical trial, and assess the applications of emerging approaches based on available data on their efficacy and safety, Develop personalized management plans for patients with newly diagnosed and recurrent GBM, including within the context of clinical trials, based on the current clinical evidence, guideline recommendations, and patient needs and preferences.

Go online to PeerView.com/EWB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How do your colleagues incorporate the latest research and guideline recommendations into the clinical management of patients with glioblastoma multiforme (GBM)? With a median overall survival of only 15 months, GBM has long presented a challenge to the multidisciplinary management team. To maximize patient survival and QOL, clinicians who treat patients with this complex, diverse, fast-growing, and aggressive brain tumor must be prepared to quickly create personalized management plans that incorporate several new modalities, including tumor treating fields (TTFields) and efficacious systemic therapies, as well as clinical trial–based options. In a new event from PeerView and the American Brain Tumor Association (ABTA), an expert panel will review the latest efficacy and safety data on multimodal GBM treatments, along with a clear rationale for selecting guideline-recommended treatments and strategies for incorporating these advances into clinical practice. This case-based activity has been designed to help clinicians hone their informed decision-making skills and personalize management plans and for the benefit of patients with GBM in a variety of settings. Upon completion of this CE activity, participants will be able to: Describe the biologic rationale and latest clinical evidence for the use of guideline-recommended treatment strategies, such as TTFields and multikinase and TRK inhibitors, for patients with newly diagnosed and recurrent GBM, Identify patients with GBM who may benefit from participation in a clinical trial, and assess the applications of emerging approaches based on available data on their efficacy and safety, Develop personalized management plans for patients with newly diagnosed and recurrent GBM, including within the context of clinical trials, based on the current clinical evidence, guideline recommendations, and patient needs and preferences.

Go online to PeerView.com/EWB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How do your colleagues incorporate the latest research and guideline recommendations into the clinical management of patients with glioblastoma multiforme (GBM)? With a median overall survival of only 15 months, GBM has long presented a challenge to the multidisciplinary management team. To maximize patient survival and QOL, clinicians who treat patients with this complex, diverse, fast-growing, and aggressive brain tumor must be prepared to quickly create personalized management plans that incorporate several new modalities, including tumor treating fields (TTFields) and efficacious systemic therapies, as well as clinical trial–based options. In a new event from PeerView and the American Brain Tumor Association (ABTA), an expert panel will review the latest efficacy and safety data on multimodal GBM treatments, along with a clear rationale for selecting guideline-recommended treatments and strategies for incorporating these advances into clinical practice. This case-based activity has been designed to help clinicians hone their informed decision-making skills and personalize management plans and for the benefit of patients with GBM in a variety of settings. Upon completion of this CE activity, participants will be able to: Describe the biologic rationale and latest clinical evidence for the use of guideline-recommended treatment strategies, such as TTFields and multikinase and TRK inhibitors, for patients with newly diagnosed and recurrent GBM, Identify patients with GBM who may benefit from participation in a clinical trial, and assess the applications of emerging approaches based on available data on their efficacy and safety, Develop personalized management plans for patients with newly diagnosed and recurrent GBM, including within the context of clinical trials, based on the current clinical evidence, guideline recommendations, and patient needs and preferences.

Go online to PeerView.com/EWB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How do your colleagues incorporate the latest research and guideline recommendations into the clinical management of patients with glioblastoma multiforme (GBM)? With a median overall survival of only 15 months, GBM has long presented a challenge to the multidisciplinary management team. To maximize patient survival and QOL, clinicians who treat patients with this complex, diverse, fast-growing, and aggressive brain tumor must be prepared to quickly create personalized management plans that incorporate several new modalities, including tumor treating fields (TTFields) and efficacious systemic therapies, as well as clinical trial–based options. In a new event from PeerView and the American Brain Tumor Association (ABTA), an expert panel will review the latest efficacy and safety data on multimodal GBM treatments, along with a clear rationale for selecting guideline-recommended treatments and strategies for incorporating these advances into clinical practice. This case-based activity has been designed to help clinicians hone their informed decision-making skills and personalize management plans and for the benefit of patients with GBM in a variety of settings. Upon completion of this CE activity, participants will be able to: Describe the biologic rationale and latest clinical evidence for the use of guideline-recommended treatment strategies, such as TTFields and multikinase and TRK inhibitors, for patients with newly diagnosed and recurrent GBM, Identify patients with GBM who may benefit from participation in a clinical trial, and assess the applications of emerging approaches based on available data on their efficacy and safety, Develop personalized management plans for patients with newly diagnosed and recurrent GBM, including within the context of clinical trials, based on the current clinical evidence, guideline recommendations, and patient needs and preferences.

Go online to PeerView.com/EWB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How do your colleagues incorporate the latest research and guideline recommendations into the clinical management of patients with glioblastoma multiforme (GBM)? With a median overall survival of only 15 months, GBM has long presented a challenge to the multidisciplinary management team. To maximize patient survival and QOL, clinicians who treat patients with this complex, diverse, fast-growing, and aggressive brain tumor must be prepared to quickly create personalized management plans that incorporate several new modalities, including tumor treating fields (TTFields) and efficacious systemic therapies, as well as clinical trial–based options. In a new event from PeerView and the American Brain Tumor Association (ABTA), an expert panel will review the latest efficacy and safety data on multimodal GBM treatments, along with a clear rationale for selecting guideline-recommended treatments and strategies for incorporating these advances into clinical practice. This case-based activity has been designed to help clinicians hone their informed decision-making skills and personalize management plans and for the benefit of patients with GBM in a variety of settings. Upon completion of this CE activity, participants will be able to: Describe the biologic rationale and latest clinical evidence for the use of guideline-recommended treatment strategies, such as TTFields and multikinase and TRK inhibitors, for patients with newly diagnosed and recurrent GBM, Identify patients with GBM who may benefit from participation in a clinical trial, and assess the applications of emerging approaches based on available data on their efficacy and safety, Develop personalized management plans for patients with newly diagnosed and recurrent GBM, including within the context of clinical trials, based on the current clinical evidence, guideline recommendations, and patient needs and preferences.

Go online to PeerView.com/EWB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How do your colleagues incorporate the latest research and guideline recommendations into the clinical management of patients with glioblastoma multiforme (GBM)? With a median overall survival of only 15 months, GBM has long presented a challenge to the multidisciplinary management team. To maximize patient survival and QOL, clinicians who treat patients with this complex, diverse, fast-growing, and aggressive brain tumor must be prepared to quickly create personalized management plans that incorporate several new modalities, including tumor treating fields (TTFields) and efficacious systemic therapies, as well as clinical trial–based options. In a new event from PeerView and the American Brain Tumor Association (ABTA), an expert panel will review the latest efficacy and safety data on multimodal GBM treatments, along with a clear rationale for selecting guideline-recommended treatments and strategies for incorporating these advances into clinical practice. This case-based activity has been designed to help clinicians hone their informed decision-making skills and personalize management plans and for the benefit of patients with GBM in a variety of settings. Upon completion of this CE activity, participants will be able to: Describe the biologic rationale and latest clinical evidence for the use of guideline-recommended treatment strategies, such as TTFields and multikinase and TRK inhibitors, for patients with newly diagnosed and recurrent GBM, Identify patients with GBM who may benefit from participation in a clinical trial, and assess the applications of emerging approaches based on available data on their efficacy and safety, Develop personalized management plans for patients with newly diagnosed and recurrent GBM, including within the context of clinical trials, based on the current clinical evidence, guideline recommendations, and patient needs and preferences.

Episode 48 - On this episode, we chat to two Tassie locals, Brent Bowerman (The Lost Fly) and Simon Ellis about the unique Black Bream fishery in Tasmania. Tasmania is known for its world class Trout fishery but this often overshadows the incredible Black Bream fishery they have as well. On this show, we chat about Brem techniques, but we also talk about attitudes changing towards flyfishing options in a very "Trout-centric" part of Australia. Also on this show we learn about "Magging" and we also open up debate about Fly V Lure when it comes to material selection and what you define as a fly.

Mat Best is a former U.S. Army Ranger who was deployed five times to Iraq & Afghanistan. Mat created his first YouTube video in 2012, and now his social media presence has accumulated to more than 3 million subscribers with hundreds of millions of views. Mat is the co-founder of three successful businesses: Black Rifle Coffee, Leadslingers Whiskey, and Article 15 Clothing. He co-produced the independent feature film Range 15, and last week hit the NYTimes bestseller list with his new book, Thank You For My Service. Here's what we cover with Mat in this informative yet very entertaining interview.   When people ask Mat what he does, how does he like to reply? What did Mat learn about himself by writing the book? Ryan Munsey said he always asks himself, "what is the author trying to say?" What was Mat trying to say? For who is the book written? Does Mat remember first thinking he would use humour to not take life too seriously? How did Mat feel inside when he heard his brother had cancer? What's Gallows Humour? In a fire fight when the action is over, the adrenaline dump takes hold of you. How did Mat deal with that adrenaline dump? Mat was obsessed with the act of war. What was that addiction? Did the experience of war ever sit deep in his soul waiting to come to the surface? The moment when two buddies were severely injured, and Matt comes to understand true brotherhood. Has Mat found that same feeling outside of the military? At Arlington Cemetery Mat, buried Brem and Baraza. What values does he take from the memory of these two heroes? Is Mat the sort of guy who has a vision of what he wants to do next? With his light-hearted approach to situations, life, and leadership roles, where is the sweet spot? With Mat's carefree black humour approach to life, did he ever find he had a hard time taking orders or respecting command? Does boredom fuel his creativity… video, movies, coffee, merchandise design, books? What is Mat's work ethic like today? Focus, discipline, planning? From the age of 17 to 23, Mat was a Ranger, that was his identity. What's his identity today? The mission behind BRCC? Can we create true camaraderie in our companies that give us the same camaraderie Mat had in the military? How has he embedded the mission through every level of the company? Many people misrepresent what military culture is all about. What is it about? Mat is fourth-generation military; did he feel any pressure with that legacy? If Mat had another go after leaving the military, how would he approach it? How would he course correct? Black Hawk Down, what was it about that film, a scene, a moment that resonated for Mat?   LINKS   Mat Best at Black Rifle Coffee Company https://www.blackriflecoffee.com/pages/mat-best-1   Mat on Instagram https://www.instagram.com/mat_best_official/?hl=en   Mat's book "Thank You for My Service”. www.thankyouformyservice.com   Mat on Youtube https://www.youtube.com/channel/UCre2GibO9Vdb3C59VzDsFxQ   The Mojo Radio Show on Patreon https://www.patreon.com/themojoradioshowpodcast   The Mojo Radio Show http://www.themojoradioshow.com   The Mojo Radio Show on Facebook https://www.facebook.com/TheMojoRadioShowPodcast/   The Mojo Radio Show on Twitter https://twitter.com/tmrspod   The Mojo Radio Show Answering Machine 08 7200 6656 08 7200 MOJO   The Mojo Radio Show copyright Gary Bertwistle & Darren Robertson...

profil-Kolumnistin Elfriede Hammerl spricht mit der Geschäftsführerin der Wiener Frauenhäuser Andrea Brem über 40 Jahre Frauenschutz, wie das Internet die Gewalt verändert hat und was die Justiz in Österreich noch lernen muss.